Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Anaïs Saint-Martin WillerHypertension Pulmonaire : Physiopathologie and Innovation Thérapeutique (HPPIT), Université Paris-Saclay, Inserm, UMR_S 999, AP-HP, Hôpital Bicêtre, Hôpital Marie Lannelongue (Groupe Hospitalier Paris Saint Joseph), ERN-LUNG, Le Plessis Robinson, France.ORCID http://orcid.org/0000-0002-2078-3271
Bastien MassonHypertension Pulmonaire : Physiopathologie and Innovation Thérapeutique (HPPIT), Université Paris-Saclay, Inserm, UMR_S 999, AP-HP, Hôpital Bicêtre, Hôpital Marie Lannelongue (Groupe Hospitalier Paris Saint Joseph), ERN-LUNG, Le Plessis Robinson, France.ORCID http://orcid.org/0000-0003-2364-5269
Loann LaubryHypertension Pulmonaire : Physiopathologie and Innovation Thérapeutique (HPPIT), Université Paris-Saclay, Inserm, UMR_S 999, AP-HP, Hôpital Bicêtre, Hôpital Marie Lannelongue (Groupe Hospitalier Paris Saint Joseph), ERN-LUNG, Le Plessis Robinson, France.ORCID http://orcid.org/0000-0002-1748-6110
Mary DutheilHypertension Pulmonaire : Physiopathologie and Innovation Thérapeutique (HPPIT), Université Paris-Saclay, Inserm, UMR_S 999, AP-HP, Hôpital Bicêtre, Hôpital Marie Lannelongue (Groupe Hospitalier Paris Saint Joseph), ERN-LUNG, Le Plessis Robinson, France.
Kristelle El JekmekHypertension Pulmonaire : Physiopathologie and Innovation Thérapeutique (HPPIT), Université Paris-Saclay, Inserm, UMR_S 999, AP-HP, Hôpital Bicêtre, Hôpital Marie Lannelongue (Groupe Hospitalier Paris Saint Joseph), ERN-LUNG, Le Plessis Robinson, France.ORCID http://orcid.org/0009-0004-3871-1163
Marc HumbertHypertension Pulmonaire : Physiopathologie and Innovation Thérapeutique (HPPIT), Université Paris-Saclay, Inserm, UMR_S 999, AP-HP, Hôpital Bicêtre, Hôpital Marie Lannelongue (Groupe Hospitalier Paris Saint Joseph), ERN-LUNG, Le Plessis Robinson, France.ORCID http://orcid.org/0000-0003-0703-2892
Olaf MercierHypertension Pulmonaire : Physiopathologie and Innovation Thérapeutique (HPPIT), Université Paris-Saclay, Inserm, UMR_S 999, AP-HP, Hôpital Bicêtre, Hôpital Marie Lannelongue (Groupe Hospitalier Paris Saint Joseph), ERN-LUNG, Le Plessis Robinson, France.ORCID http://orcid.org/0000-0002-4760-6267
Grégoire RuffenachHypertension Pulmonaire : Physiopathologie and Innovation Thérapeutique (HPPIT), Université Paris-Saclay, Inserm, UMR_S 999, AP-HP, Hôpital Bicêtre, Hôpital Marie Lannelongue (Groupe Hospitalier Paris Saint Joseph), ERN-LUNG, Le Plessis Robinson, France.ORCID http://orcid.org/0000-0001-6419-4332
David MontaniHypertension Pulmonaire : Physiopathologie and Innovation Thérapeutique (HPPIT), Université Paris-Saclay, Inserm, UMR_S 999, AP-HP, Hôpital Bicêtre, Hôpital Marie Lannelongue (Groupe Hospitalier Paris Saint Joseph), ERN-LUNG, Le Plessis Robinson, France.ORCID http://orcid.org/0000-0002-9358-6922
Véronique CapuanoHypertension Pulmonaire : Physiopathologie and Innovation Thérapeutique (HPPIT), Université Paris-Saclay, Inserm, UMR_S 999, AP-HP, Hôpital Bicêtre, Hôpital Marie Lannelongue (Groupe Hospitalier Paris Saint Joseph), ERN-LUNG, Le Plessis Robinson, France.ORCID http://orcid.org/0000-0001-8738-0947
Fabrice AntignyHypertension Pulmonaire : Physiopathologie and Innovation Thérapeutique (HPPIT), Université Paris-Saclay, Inserm, UMR_S 999, AP-HP, Hôpital Bicêtre, Hôpital Marie Lannelongue (Groupe Hospitalier Paris Saint Joseph), ERN-LUNG, Le Plessis Robinson, France. fabrice.antigny@inserm.fr.ORCID http://orcid.org/0000-0002-9515-6571
Funding
Fondation Maladies Rares and AFM-Téléthon #POCs(2023)-121503
6 · The paper itself
Abstract
BACKGROUND-: Pulmonary arterial hypertension (PAH) is a rare, fatal, and progressive pulmonary vascular disease. Pulmonary endothelial cell dysfunction is a hallmark of PAH, defined by excessive proliferation and dysregulated angiogenesis, along with imbalanced production and release of vasoactive substances, growth factors, and mediators of coagulation and inflammation. Intracellular calcium (Ca2+) variations are essential in these processes. Among the various channels involved in Ca2+ homeostasis, transient receptor potential canonical channels (TRPC1 to 7) are known to be essential for endothelial cells of various origins, but their role in PAH remains unknown. RESULTS-: We found that four TRPC channels (TRPC1, TRPC3, TRPC4, and TRPC6) were expressed in human pulmonary endothelial cells (hPECs) from control and PAH patients. By knocking down each of these channels in hPECs isolated from PAH patients (PAH-hPECs), we found that TRPC1 and TRPC4 are involved in store-operated Ca2+ entry (SOCE). We showed that TRPC1 and TRPC3 are essential for PAH-hPECs proliferation and that TRPC3, TRPC4, and TRPC6 are important for mitogenic crosstalk in the PAH-hPECs medium. Moreover, we showed that none of the TRPC channels is involved in the migration or in vitro tubulogenesis of PAH-hPECs. Finally, we found that TRPC1 knockdown induces changes in the mRNA expression of several genes described to be crucial for endothelial cell homeostasis. CONCLUSIONS-: These data demonstrate that TRPC channels, especially TRPC1, are essential for maintaining the hPECs function in PAH, indicating that TRPC channels are central and represent interesting candidates for reducing endothelial dysfunction in PAH.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
TRPC channels contribute to endothelial dysfunction in pulmonary arterial hypertension. · full record | OpenQuestion